Neuanfang Nexmed nach R/S - 500 Beiträge pro Seite

[Hunter20nov]

So mal neuen Thread anfangen da der alte nicht mehr weitergeführt werden kann nach R/S bzw. neue WKN

Hoffe gestern haben alle den Anstieg von 2,5 bis auch 3,80 $ mitbekommen denke nun gehts erstmal ne Weile aufwärts.

Grüße

[Hunter20nov]

07.07.2010 14:34
NexMed Regains Compliance with NASDAQ Listing Requirements


NexMed, Inc. (Nasdaq: NEXMD), a specialty CRO with a pipeline of product candidates based on the NexACT® technology, today announced that the Company received a letter, dated July 6, 2010 from The NASDAQ Hearings Panel (the "Panel"), stating that it has met the requirements of the Panel's decision dated December 17, 2009, as modified February 1, 2010, and the applicable requirements for listing on The NASDAQ Stock Market. Accordingly, the Panel has determined to continue the listing of the Company's securities on The NASDAQ Stock Market.

Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, noted, "Overcoming the series of deficiencies we have had since October 2008 has been a major objective for management and a noteworthy accomplishment for the Company. Meeting our NASDAQ milestone is the first of many in our growth strategy for 2010 and beyond."

About NexMed

NexMed is the largest specialty CRO based in San Diego, CA and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models. The Company's goal is to generate revenues from the growth of its Discovery Pre-clinical CRO business, while aggressively seeking to monetize its proprietary NexACT drug delivery technology through out-licensing agreements with pharmaceutical and biotechnology companies, worldwide. At the same time, NexMed is actively pursuing partnering opportunities for its NexACT-based treatments for onychomycosis, psoriasis, sexual dysfunction and cancer. For further information on NexMed and its subsidiaries, visit the following websites: http://www.nexmed.com or http://www.bio-quant.com.

Contacts:

NexMed, Inc.
Edward Cox, 858-926-5811
V.P. Investor Relations
[e-mail]
or
NexMed Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
[e-mail]


© 2010 Business Wire


Quelle : http://www.finanznachrichten.de/nachrichten-2010-07/1734802…

[hennep]

Antwort auf Beitrag Nr.: 39.785.720 von Hunter20nov am 07.07.10 08:49:13

Erstmal Danke Hunter...........:-)
Ja war ein schöner Anstieg nach den vielen red days............!
We will see...............,

Gruß

Hennep

[Hunter20nov]

na noch sucht se sich den Boden aber ich denke nun hat sie ihn gefunden. Schauen wir mal wie es weiter geht.

bin nur überrascht wo ich gesehen habe das nur noch ca. 7,6 Mio Aktien geben sollte hatte eigentlich nach dem Splitt mit 18 Mio gerechnet nur wo ist der Rest.... ? Entweder habe
tomaten auf den Augen oder konnte es nicht finden aber eigentlich hätte nach dem Splitt (1:15 ) 18 Mio Aktien über bleiben sollen aber nun sind wa bei nur fast achte.

Aber sei es drum ist ja gut für uns da durch die Enge der Preis (hoffe ich ) nach oben gebracht wird. Eine richtig gute Nachricht und der Sprung auf 5 $ sollte dann nen Klacks sein.

Grüße

[Hunter20nov]

10.09.2010 22:32
NexMed, Inc. Announces Results of Special Meeting of Stockholders, Including Name Change to Apricus Biosciences

NexMed, Inc. (Nasdaq:NEXM), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, announced the results of its Special Meeting of Stockholders, held today, Friday, September 10, 2010.

At the Special Meeting, the Stockholders of the Company approved, by an affirmative majority vote, to change the name of the Company from NexMed, Inc. to Apricus Biosciences, Inc. ("Apricus Bio"), effective September 10, 2010. The name change was brought on to reflect the broader focus of the Company's development programs. The Company's common stock will commence trading under the symbol, NASDAQ: APRI, effective at the open of the market on Tuesday, September 14, 2010.

Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, commented, "Beginning with the acquisition of Bio-Quant by NexMed in late 2009, we have undertaken a number of positive changes that are expected to reshape the Company over the long-term. In particular, we have expanded our product pipeline, re-energized the development of the NexACT technology as a drug delivery platform and have begun active licensing efforts for both proprietary programs, as well as third party programs enhanced with the NexACT technology. Additionally, we have leveraged Bio-Quant's CRO capabilities to help advance new applications for NexACT. The rebranding of the Company at this time is part of our broader effort to alert potential development partners and the investment community of our new business model."

In connection with the Company's name change, management expects to launch its new website, http://www.apricusbio.com on Tuesday, September 14, 2010.

In addition, the Stockholders approved, by an affirmative majority vote, to increase the number of shares of Common Stock authorized for issuance by the Company from 18,000,000 shares to 75,000,000 shares.

About Apricus Biosciences

Backed by a solid, revenue generating CRO business, Bio-Quant, Inc., and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on the Company and its subsidiaries, visit http://www.nexmed.com.

Contacts:

Apricus Biosciences, Inc.
Edward Cox, 858-926-5811
V.P. Investor Relations
[e-mail]
or
Investor Relations:
Rx Communications Group, LLC
Paula Schwartz, 917-322-2216
[e-mail]


© 2010 Business Wire

http://www.finanznachrichten.de/nachrichten-2010-09/1793234…